| Literature DB >> 16156898 |
Giancarlo Ghiselli1, Chang-Gong Liu.
Abstract
BACKGROUND: The Structural Maintenance of Chromosome 3 protein (SMC3) plays an essential role during the sister chromatid separation, is involved in DNA repair and recombination and participates in microtubule-mediated intracellular transport. SMC3 is frequently elevated in human colon carcinoma and overexpression of the protein transforms murine NIH3T3 fibroblasts. In order to gain insight into the mechanism of SMC3-mediated tumorigenesis a gene expression profiling was performed on human 293 cells line stably overexpressing SMC3.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16156898 PMCID: PMC1242249 DOI: 10.1186/1476-4598-4-34
Source DB: PubMed Journal: Mol Cancer ISSN: 1476-4598 Impact factor: 27.401
Figure 1Identification and characterization of 293 cells stably overexpressing human SMC3. a): 293 cells were transfected with SMC3-pcDNA3.1 expression vector or the empty vector alone. Cell clones with stably integrated vector were selected in medium containing 500 μg/ml of G418 for three weeks. The expression of SMC3 and of the housekeeping gene G3DPH in drug-resistant clones was evaluated by semi-quantitative RT-PCR. b): SMC3 expression analysis was repeated on cells at later passages to confirm that clones stably overexpressing SMC3 were used. This time SMC3 expression was examined by Western immunoblotting. For this purpose cells were solubilized in lysis buffer and analyzed by 8% SDS-PAGE. After transfer of the proteins to nitrocellulose, SMC3 was immunodetected using a goat polyclonal antibody followed by ECL detection of the immunocomplex. The expression of α-tubulin was used to assess the inter-sample variability using nitrocellulose filters stripped of the SMC3 immunocomplexes.
Significantly regulated genes in SMC3 overexpressing 293 cells. Human expressed sequence tags and genes with no known function are not included. Complete results of the array have been submitted to the EBI microarray database.
| GPC3, glypican 3 | 2.55 | 2.49 |
| lectin, mannose-binding, 1 like | 2.05 | 2.13 |
| HAS2, hyaluronan synthase 2 | 1.89 | 2.03 |
| LAMB3, lamin, beta 3 | -1.99 | -3.76 |
| ATP6V1B1, ATPase, H+ transporting V1 subunit B, kidney isoform | 3.15 | 2.40 |
| KCTD12, potassium channel tetramerisation domain 12 | 1.85 | 2.02 |
| SLC7A10, solute carrier family 7 member 10, neutral amino acid transporter | -2.00 | -2.00 |
| MIG12, MID1 interacting G12-like protein | 2.58 | 2.65 |
| CKB, creatine kinase, B chain | 2.00 | 2.28 |
| ECHDC3, enoyl Coenzyme A hydratase domain containing 3 | 2.25 | 2.20 |
| ALDH1A3, aldehyde dehydrogenase 1 family, member A3 | 1.94 | 2.16 |
| MOXD1, monooxygenase, DBH-like 1 | 2.53 | 2.05 |
| TXNRD3, thioredoxin reductase 3 | 1.81 | 2.00 |
| LTBP2, latent transforming growth factor beta binding protein 2 | 1.95 | 2.68 |
| GABRE, gamma-aminobutyric acid A receptor, epsilon | 2.04 | 2.54 |
| DLL1, delta-like 1, notch ligand | 1.83 | 2.23 |
| GDF9, growth differentiation factor 9 | 1.88 | 2.19 |
| IGFBP7, insulin-like growth factor binding protein 7 | 1.81 | 2.15 |
| GNRH1, gonadotropin-releasing hormone 1 | 2.23 | 2.04 |
| IRAK1, interleukin-1 receptor associated kinase 1 | -2.17 | -2.13 |
| EGFL3, EGF-like-domain, multiple 3 | -2.20 | -2.16 |
| IL22RA1, interleukin 22 receptor, alpha 1 | -2.22 | -2.48 |
| OR4D1, olfactory receptor, family 4, subfamily D, member 1 | -1.91 | -3.03 |
| GRB7, growth factor receptor-bound protein 7 | -2.20 | -4.18 |
| ARHGEF4, Rho guanine nucleotide exchange factor 4 | 2.36 | 2.85 |
| RGS14, regulator of G-protein signaling 14 | 2.17 | 2.57 |
| RPS6KA5, ribosomal protein S6 kinase, polypeptide 5 | 2.09 | 2.46 |
| PAK6, p21-activated kinase 6 | 2.16 | 2.38 |
| RIN3, Ras and Rab interactor 3 | 1.86 | 2.19 |
| RHOB, ras homolog gene family, member B | 1.81 | 2.18 |
| SCFD1, sec1 family domain containing 1 | 2.31 | 2.08 |
| LRRK1, leucine-rich repeat kinase 1 | 2.16 | 2.06 |
| RAB40B, GTP-binding protein 40B | 1.91 | 2.15 |
| PDE6B, phosphodiesterase 6B, cGMP-specific | 2.02 | 2.09 |
| MCF2L, MCF.2 cell line derived transforming sequence | -1.92 | -2.16 |
| S100A8, S 100 calcium binding protein A8, calgranulin A | -1.92 | -2.86 |
| ADCY2, adenylate cyclase 2 | -1.92 | -3.03 |
| MEOX2, mesenchyme homeobox 2, growth arrest specific homeobox | 2.14 | 3.96 |
| IRF4, interferon regulatory factor 4 | 2.20 | 3.28 |
| KHDRBS3, KH domain, RNA binding, signal transduction associated 3 | 2.24 | 2.62 |
| PPARA, peroxisome proliferative activated receptor, alpha | 2.22 | 2.50 |
| CRE-BPa, cAMP responsive element binding protein, ATF2-like | 1.94 | 2.37 |
| NEK9, never-in-mitosis-gene a-related kinase 9 | 1.83 | 2.33 |
| CREM, cAMP responsive element modulator | -1.87 | -2.11 |
| NCOA6, nuclear receptor coactivator 6 | -1.88 | -2.32 |
| TXB21, T-box 21 | -1.88 | -2.42 |
| POU3F1, POU domain, class 3, octamer-binding TF6 | -2.21 | -2.44 |
| NKX6-1, NK6 transcriptional factor related, locus 1, homeobox 6A | -1.90 | -2.53 |
| CTNNA1, catenin alpha 1 | -1.90 | -2.57 |
| BCL6B, B-cell CLL/lymphoma 6, member B zinc finger protein | -2.72 | -2.79 |
| ZNF236, zinc finger protein 236 | -1.90 | -3.11 |
| MHL3, mutL homolog 3 | 2.76 | 2.81 |
| DNMT2, DNA cytosine-5-methyltransferase 2 | 1.88 | 2.07 |
| ADPRTL2, ADP-ribosyltransferase 2 | 2.11 | 2.00 |
| SNRPN, small nuclear ribonuclear polypeptide N | -2.25 | -2.64 |
| MYOM2, myomesin 2 | 2.77 | 5.10 |
| NOPE, neighbor of Punc E11 | 2.53 | 2.56 |
| C5, complement component 5 | 2.09 | 2.46 |
| COCH, coagulation factor C homolog, cochlin | 2.15 | 2.09 |
| VMD2L1, vitelliform macular dystrophy 2-like 1 | -2.17 | -2.09 |
| GRN, granulin | -1.94 | -2.14 |
| HPN, hepsin serine protease | -2.02 | -2.27 |
| LPHN1, latrophilin 1 | -1.90 | -2.38 |
| PRND, prion protein 2 | -2.01 | -2.50 |
| HYPM, huntingtin interacting protein M | -2.18 | -3.98 |
Figure 2Two-class analysis of the microarray data set. The six 293 cells arrays (three from the control clones, and three from the SMC3-overexpressing clones) were subjected to SAM two-class unpaired analysis where the software created a field of observed versus expected gene regulation values from the array data. A delta parameter (0.409) was chosen to limit the field and provide the optimal output of significantly to falsely significantly regulated genes (16 in our analysis). The threshold was set at 1.00 corresponding to a twofold difference in regulation from the control cells when data are entered as log2 values. Dashed lines: delta parameter which defines the significance field; dots above the upper line: probable significantly up-regulated genes; dots below the lower line: probable significantly down-regulated genes.
Figure 3Effect of SMC3 overexpression on 293 cells colony growth. a): 293 cells at 70% confluence were transfected with 1 μg/ml of pcDNA3.1 (control) or SMC3-pcDNA3.1 expression vectors and cell RNA collected after 48 hrs in 1 ml TriReagent. SMC3, and G3PDH transcript levels were assayed by semiquantitative RT-PCR and the products analyzed by agarose electrophoresis. The result of a control and two independent samples of cells transfected with SMC3-pcDNA3.1 are shown. b) Growth rate of cells overexpressing SMC3. Cells were seeded in 96-well plates (2,500 cells/well in a final volume of 150 μl) in DMEM medium supplemented with 1.5% FCS. Cell proliferation was assessed by using a CellTiter 96 colorimetric assay. Each point represent the mean ± SD of four independent determinations. c,d) Transfected cells were seeded in 35 mm plates and grown for 10 days in DMEM supplemented with 1.5% FCS. To detect foci of transformation, cells were fixed in 70% ethanol followed by staining with 0.1% methylene-blue. e,f) Colony formation in semisoft agarose. Twenty-four h after transfection, cells were trypsinized and resuspended in 0.2% agarose in DMEM containing 10% fetal bovine serum and plated on top of solidified agarose (0.4%) dissolved in the same medium in 35 mm dishes. After 3 weeks of culture cell colonies were examined under a light microscope.
Figure 4Effect of SMC3 on the expression of a set of early-response genes. a) Cells were transfected with 1 μg/ml of pcDNA3.1 (control) or SMC3-pcDNA3.1 and RNA collected after 48 hrs in 1 ml TriReagent. Gene transcripts were amplified by RT-PCR and the products analyzed by agarose electrophoresis. b) Analysis of RhoB level in NIH-3T3 and 293 cells overexpressing SMC3. Cells were transfected as in a) and 48 h later solubilized in lysis buffer. Twenty and 50 μg respectively of NIH-3T3 and 293 cell lysate proteins were analyzed by 12.5% SDS-PAGE. After transfer to nitrocellulose, RhoB was immunodetected using a rabbit polyclonal antibody followed by ECL detection of the immunocomplex. Nitrocellulose-bound proteins were stained with Ponceau-red to evidence the amount of proteins loaded.
Figure 5Transcriptional activity in control and SMC3 overexpressing cells. Cells were seeded in 12 well plates and used at 70% confluence. Treatment groups, each as triplicate samples, were transfected with 0.1 μg/ml of the indicated reporter vector together with 0.01 μg/ml of PH-RL transfection control vector using 5 μl/ml Lipofectamine. The reporter vectors harbor multiple repeats of the consensus sequence for different transcriptional binding sites which drive the expression of a firefly luciferase. Transactivation activity was calculated based on the firefly luciferase level correcting for the transfection efficiency using the renilla luciferase level in a dual luciferase assay. Data shown are the mean ± SD from three independent determinations. * p < 0.01 SMC3-overexpressing vs. control.